Susova O Y, Karshieva S S, Kostyukov A A, Moiseeva N I, Zaytseva E A, Kalabina K V, Zusinaite E, Gildemann K, Smirnov N M, Arutyunyan A F, Zhuze A L
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health, Moscow, 115522 Russian Federation.
Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, 119334 Russian Federation.
Acta Naturae. 2024 Jan-Mar;16(1):86-100. doi: 10.32607/actanaturae.27327.
Its broad spectrum of biological activity makes benzimidazole a fundamental pharmacophore in pharmaceutics. The paper describes newly synthesized AT-specific fluorescent bis-benzimidazole molecules DB2Py(n) that contain a pyrrolcarboxamide fragment of the antibiotic drug netropsin. Physico-chemical methods using absorption, fluorescence, and circular dichroism spectra have shown the ability of bis-benzimidazole- pyrroles to form complexes with DNA. The new DB2Py(n) series have turned out to be more toxic to human tumor lines and less vulnerable to non-tumor cell lines. Bis-benzimidazole-pyrroles penetrated the cell nucleus, affected the cell-cycle synthesis (S) phase, and inhibited eukaryotic topoisomerase I in a cellfree model at low concentrations. A real-time tumor cell proliferation test confirmed the molecule's enhanced toxic properties upon dimerization. Preliminary cytotoxicity data for the bis-benzimidazole-pyrroles tested in a cell model with a MDR phenotype showed that monomeric compounds can overcome MDR, while dimerization weakens this ability to its intermediate values as compared to doxorubicin. In this respect, the newly synthesized cytotoxic structures seem promising for further, in-depth study of their properties and action mechanism in relation to human tumor cells, as well as for designing new AT-specific ligands.
苯并咪唑广泛的生物活性使其成为药物制剂中的一种基本药效基团。本文描述了新合成的具有AT特异性的荧光双苯并咪唑分子DB2Py(n),其含有抗生素药物纺锤菌素的吡咯甲酰胺片段。利用吸收光谱、荧光光谱和圆二色光谱的物理化学方法表明,双苯并咪唑-吡咯能够与DNA形成复合物。新的DB2Py(n)系列对人类肿瘤细胞系毒性更大,对非肿瘤细胞系的敏感性更低。双苯并咪唑-吡咯可穿透细胞核,影响细胞周期合成(S)期,并在无细胞模型中以低浓度抑制真核拓扑异构酶I。实时肿瘤细胞增殖试验证实了该分子二聚化后毒性增强。在具有多药耐药(MDR)表型的细胞模型中测试的双苯并咪唑-吡咯的初步细胞毒性数据表明,单体化合物可以克服MDR,而与阿霉素相比,二聚化会使其这种能力减弱至中间值。在这方面,新合成的细胞毒性结构似乎有望进一步深入研究其与人类肿瘤细胞相关的性质和作用机制,以及设计新的AT特异性配体。